Search
Kymera Therapeutics Inc
KYMRAdd to Watchlist
126.630USD
+4.030+3.29%
Close 10-30 16:00（ET）
10.53BMarket Cap
LossP/E TTM
Kymera Therapeutics Inc (KYMR) Stock Price Target & Forecast
Analyst Rating
Based on 24 analysts giving stock ratings to Kymera Therapeutics Inc in the past month.
Buy
9 Strong Buy
13 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
139.818USD+14.13%
KYMR Analyst Recommendation Trends
In the current month, KYMR has received 13 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. KYMR average Analyst price target in the last month is 139.818.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
9
9
8
8
8
9
9
9
13
13
13
13
14
14
13
13
2
2
3
3
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
24
24
24
24
23
24
23
23
KYMR Analyst Rating for Peer Comparison
Updated: Nov 1, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
11
8
0
0
23
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Cytokinetics Inc
CYTK
5
15
2
0
0
22
Financial Forecasting
Based on analysts' estimates, KYMR EPS is projected to reach -1.288 in FY2026Q4, following reported EPS of -1.319 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.88
-0.71
-1.27
-1.29
-1.36
Actual
-0.71
-0.62
-1.32
--
--
Surprise
+19.49%
+12.56%
-3.80%
--
--
FAQs
What is Kymera Therapeutics Inc's expected revenue for the next quarter?
Kymera Therapeutics Inc's expected revenue is 2.87M.
What is Kymera Therapeutics Inc's price target?
Analysts forecast that Kymera Therapeutics Inc's price target is USD 139.82, with the highest forecast at USD 180.00 and the lowest forecast at USD 111.00.
How have Kymera Therapeutics IncKYMR's recent earnings per share performed?
The market expectation was USD -1.32, while Kymera Therapeutics IncKYMR's earnings per share (EPS) for the previous quarter was USD -0.62. EPS for the next quarter is expected at USD -1.29.
What is the analyst rating for Kymera Therapeutics Inc?
Based on the ratings of Kymera Therapeutics Inc's stock from 24 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.